Translational psychopharmacology: Novel Targets and Biomarkers

Psychiatric disorder management and care has entered a new development cycle towards a personalized medicine era. In this context, research in the Translational psychopharmacology: Novel Targets and Biomarkers aims to promote innovation and continuous exchange with shareholders and stakeholders towards patented novel pharmacological, predictive and prognostic approaches in psychiatry. Spanning from bench to bedside our research -is driven from our recent breakthrough work on novel targets and biomarkers (Nature Medicine, 2018; Nature Communications, 2020), -builds strong collaborative networks bringing together (i) innovative preclinical animal models, (ii) imaging (MRI, spectroscopy), (iii) coding and non-coding RNAs, (iv) bioinformatics, and -leads national (Paris Saclay-IMAGEN, AP-HP, Aix-Marseille Univ, AP-HM, CHU St Etienne) and international (PRBB/IMIM/Barcelona and Univ Basque Country/Bilbao, Spain; McGill, Canada; BROAD/McLean and Univ New Mexico, USA) multidisciplinary Consortia.

Research topics

Theme 1: Imaging gene and brain networks in stress susceptibility (GeBra);
Theme 2: Deciphering neurotransmitter vulnerability in schizophrenic patients (SchiDOTab);
Theme 3: Linking distorted cellular signaling with distorted executive processing in schizophrenia (EXEcute);
Theme 4: Biomarkers of antidepressant response ; early indicators and novel targets (ANTaRES).